Abstract Some believe that tyrosine kinase inhibitor (TKI) therapy is as close to perfect as it gets in oncologic therapy. Patients diagnosed with chronic myeloid leukemia (CML) are treated with a daily oral therapy, through which most achieve remission. TKI therapy is not associated with classic chemotherapy side effects, and most patients are able to resume their normal activities of daily living. Moreover, recent data has demonstrated that CML does not affect the life expectancy of patients whose disease is well controlled with a TKI. However, TKI therapy is actually not that perfect. Patients need to stay on therapy forever. They have to remember to take their medications daily. TKIs are expensive, and the financial burden to patient and society cannot be overstated. Most patients' health-related quality of life is affected; common side effects include fatigue, muscle cramps, pain, edema, skin problems, and gastrointestinal symptoms. In addition, concerns about long-term side effects remain. Recently several studies have shown the feasibility and safety of discontinuation in a select group of patients. Herein, we will review the currently available data on stopping TKIs in CML.
Introduction
Patients diagnosed with chronic myeloid leukemia (CML) are usually relieved to hear that treatment is with an oral therapy (not intravenous), is fairly well tolerated, and most patients will respond to this therapy. However, the life-long duration of therapy with tyrosine kinase inhibitors (TKIs) is often a disappointment, which can be experienced either at the time of diagnosis or after many years when patients are tired of taking their pills. In addition, health-related quality of life is markedly affected in many patients. Several studies published since 2010 have demonstrated the safety and feasibility of discontinuing TKI therapy in patients who have achieved a sustained deep molecular response. In this paper, we review currently available data on the safety and efficacy of stopping TKIs, starting with reasons for discontinuation.
Why Consider Stopping?
Though the survival rates for patients treated with TKIs have tremendously improved compared to previously available therapies such as interferons, it comes at a cost, both in terms of impaired health-related quality of life and significant financial burden. As CML diagnosed in chronic phase (CP-CML) is "almost" a curable disease with TKI therapy, research focus has shifted towards improving health-related quality of life, management of long-term side effects, and TKI discontinuation.
Common Side Effects
Even though the TKIs that are currently approved for treating CML are mostly well tolerated, they are also associated with significant lifestyle changes. In general, as oncologists, we This article is part of the Topical Collection on Myeloproliferative Neoplasms primarily pay attention to severe (grade 3) and life-threatening (grade 4) adverse events. However, mild (grade 1) and moderate (grade 2) adverse events play a significant role in a patient's daily routine given that the majority of patients will need to take these drugs indefinitely.
While many studies have not described patient-reported symptoms and functioning, Guerin et al. reported the impact of low-grade adverse events (grades 1 and 2) on patientreported health status in adult patients receiving imatinib or nilotinib in the ENESTnd trial [1] . Five low-grade adverse event categories-gastrointestinal disorders, blood and lymphatic system disorders, general disorders and administrative site conditions, musculoskeletal disorders, and psychiatric disorders, were associated with reduced scores on both the generic (SF-36) and leukemia-specific (FACT-LEU) patientreported outcome tools, in which low scores imply worse quality of life. These AEs were either lower with nilotinib or not different between the two drugs. One study demonstrated emotional/cognitive dysfunction with imatinib after 6 months of treatment, though clinically not significant [2] Financial Toxicity
The very high costs of TKIs is a well-known issue. In 2013, an international community of CML experts voiced concerns about the cost of these drugs, which then ranged from $92-130,000 annually [3] . Generic imatinib was introduced in 2016 at an average wholesale price of US$142,000, which was nearly the same as the US$146,000 for branded imatinib [4] . Second-generation TKIs continue to be priced even higher. With an estimated 8950 new cases of CML in 2017 [5] , and a prevalence of 48,000, the expected costs for treatment of drug alone is approximately US$5 billion annually. Not only this is a concern for society, but financial toxicity is a serious problem for patients. In 2007, 62.1% of all US bankruptcies were attributable to medical reasons, even though three quarters of these patients had health insurance, and bankruptcies attributable to medical problems rose by 49.6%, compared to 2001 [6] . High patient costs have been associated with non-adherence to TKIs in multiple studies [7, 8] .
Fertility and Pregnancy
Approximately 27% of patients diagnosed with CML are younger than 50 years old [9] .
Even though imatinib does not appear to affect men's fertility, sufficient data is not available for the other TKIs [10] . Several studies have shown an increased incidence of spontaneous abortions and congenital malformations among women who become pregnant while taking a TKI [11, 12] . Based on that, the current recommendation is to discontinue TKIs for women who wish to conceive [13] .
Children and Adolescents as a Special Group
Although CML is rare in children, they are more vulnerable to the long-term toxicities of TKIs. Growth impairment is a major adverse effect with long-term imatinib treatment in children with CML who started imatinib at a pre-pubertal age compared to those who started at pubertal age [14] . Further studies are needed to quantify this problem, particularly with newer TKIs. The most appealing strategy in this population would be to focus on true cure, rather than control of the disease with indefinite treatment.
Long-Term Adherence
Adherence to TKI therapy is essential for optimal disease control [15, 16] . Multiple studies have examined patient adherence to TKIs, which varies greatly depending on how adherence is defined and measured. One systematic review of adherence reported average adherence ranged from 19 to 100% [17] , while a recent abstract reporting a meta-analysis of 40 articles and abstracts suggested adherence of 66-75% [18] . Simple forgetfulness is one known reason for nonadherence [17] . In multiple studies, older patients and those with at least one other comorbid condition were more adherent than others [19, 20] . It should be noted that dosing and dietary requirements for each TKI differ, e.g., imatinib needs to be taken with a big meal, nilotinib on empty stomach, and dasatinib with full glass of water [21] . Concurrent treatment of GERD with a proton pump inhibitor is contraindicated with dasatinib [22] , which is another concern for some patients on this drug.
Current Data Supporting Stopping TKIs
The first study to report TKI discontinuation was the STIM1 trial, the results of which were first published in 2010 [23] and recently updated in 2017 [24••] . In the STIM1 trial, 100 adult chronic-phase CML (CP-CML) patients with sustained undetectable minimal residual disease (UMRD, MR 4.5 (4.5 log reduction/BCR-ABL ≤ 0.0032%)) for at least 2 years (6 times undetectable BCR-ABL transcripts, assessed by RT-PCR), with at least 3 years of treatment, discontinued TKI. Fifty of the participants had been previously treated with IFN-Alpha. With a median follow-up of 77 months for the whole study population, the rate of treatment-free remission (TFR) was 43% at 24 months and 38% at 60 months, despite persistent leukemic cells at low levels in most, if not all patients.
Ninety-five percent of the relapses occurred in first 7 months (80% by 3 months, median 2.5 months), with no relapses after 22 months [24••] . Treatment was restarted in 57 of 61 patients with molecular recurrence, 55 patients achieved a second UMRD with a median time of 4 months, and none experienced CML progression.
It was evident from the STIM1 trial that TKI discontinuation is safe and effective in many patients. However, many other questions remained unanswered, such as who is eligible to discontinue TKIs safely? What are the factors that predict successful discontinuation? What is the right trigger to restart TKI treatment? How is the patient's health-related quality of life affected after stopping TKIs? This led to several other large discontinuation studies across the world, in an attempt to better understand the safety and feasibility of stopping TKIs.
Who Is Eligible to Discontinue Therapy?
Duration of TKI
Based on the STIM trial criteria [23] , of at least 3 years on TKI therapy, this became the criteria for most studies (Tables 1 and 2 ). The ISAV (Imatinib Suspension and Validation) study explored minimum IM treatment duration of 24 months and showed a TFR of 51.9% at 36 months [25] . ENESTfreedom is exploring a minimum 2-year treatment with front line nilotinib (TFR of 51.6% at 48 weeks) [26] , DASfree is exploring a minimum of 2 years of dasatinib, which showed a better MMR (63%) and EFS (63%) at 1 year after discontinuation [27] . No other study has evaluated further shorter TKI therapy duration. However, several studies clearly demonstrated that a longer duration of TKI therapy predicts for better TFR [24••, 28] . Until further evidence is available from the current and future studies, it is unlikely that a shorter duration of TKI therapy would be effective in achieving a TFR.
Depth and Duration of Response
As previously mentioned, the STIM trial enrolled patients who had undetectable PCR at 4.5-log reduction for at least 2 years [24••] . More recently, the European Stop TKI trial (Euro-SKI) [29••] demonstrated that there was no difference in the rates of TFR between patients who are in MR 4, 4.5, or 5. The DESTINY trial (De-Escalation and Stopping Treatment of Imatinib, Nilotinib, or sprYcel in Chronic Myeloid Leukemia) was a TKI dose reduction to half the standard dose for 12 months prior to discontinuation. The DESTINY trial was an ambitious trial enrolling patients who are at least in MR 3 . Based on their recently presented data, the risk of relapse is higher for patients who are in MR 3 [30••] . Based on that, the minimum response depth should be MR 4 . Most studies enrolled patients who achieved a certain level of response (e.g., MR 4 or 4.5) for at least 2 years. However, the Euro-SKI [29••] and DADI [31] trial included patients who had a deep molecular response for 1 year only. In both of those studies, the duration of deep molecular response did not affect rates of TFR. As most studies included patients who were in a deep molecular response for 2 years, this is the current recommendation to consider 90 Imatinib (± prior interferon) TFR:58.5%(2 years) Imatinib withdrawal syndrome in 30% of those who discontinued imatinib; imatinib withdrawal syndrome is associated with high probability of sustained MMR TFR. However, this criteria or requirement is very difficult to apply and standardize clinically due to the variability of PCR testing and the considerable margin of error at low-level detectable disease.
Disease Phase
Limited data is available for patients who presented with accelerated or blast phase. In the ISAV study [25] , which included patients with accelerated phase at diagnosis, only two patients were enrolled with AP/BC. Specific outcomes from these two patients are not available. Based on that, no recommendations can be made for patients with AP/BC to discontinue therapy.
Prior Stem Cell Transplantation
Conversely the risk of resuming TKI for patients who have previously received a HCT seems lower. The KID study included 20 engrafted patients, who received imatinib for posttransplant relapse. At a median follow-up of 15.8 months after imatinib discontinuation, none of the 20 patients experienced UMRD loss, whereas 9 of the 28 non-transplant patients lost UMRD [32] .
Sokal Risk
High Sokal risk at diagnosis has been shown in multiple studies to predict high risk for molecular recurrence. For example, in the TWISTER study, three (75%) of four Sokal high-risk patients relapsed vs. 45% of low-risk patients [33] . 
Digital PCR
The ISAV study aimed at validating digital PCR to predict relapse after imatinib discontinuation in CML patients with undetectable Q-RT-PCR [25] . Patients were Monitored by standard Q-RT-PCR for 36 months. Patients resumed imatinib when they lost molecular remission. 48.1% relapsed with 73.1% in the first 9 months, and 14 relapsed late between 10 and 22 months. Among the 56 not-relapsed patients, 40 (37% of the total) regained Q-RT-PCR positivity but never lost MMR. dPCR results showed a significant negative predictive value ratio of 1.115. An inverse relationship between patient age and risk of relapse was also noticed: 95% of patients < 45 years relapsed vs. 42% in the class ≥ 45 to < 65 years and 33% of patients ≥ 65 years [P (χ (2)) < 0.0001]. Relapse rates ranged between 100% (< 45 years, dPCR +) and 36% (> 45 years, dPCR −) [25] . Similarly, in the A-STIM trial and KID trial, minimal residual leukemia measured by dPCR had a trend for a higher molecular relapse [28, 34, 35] .
NK Cells and Lymphocytes as Predictors of TFR
D-Stop is the prospective, multicenter discontinuation of dasatinib trial after deep MR for over 2 years and unique profiles of lymphocyte subsets for successful discontinuation in Japan [36] . This study concluded that discontinuation of dasatinib was feasible after a 2-year consolidation. Increase in lymphocytes and its subsets involving NK and NK-LGL were reported to be associated with good responses to firsttime dasatinib; these changes during consolidation after achieving DMR were negatively correlated with successful discontinuation. This unique lymphocyte changes could predict successful discontinuation. In another study by Ilander et al., patients with a higher number of NK cells and a mature NK cell subtype were more likely to stay in remission [37•] .
Do Second-Generation TKIs Lead to Better TFR?
Several studies have evaluated the role of stopping secondgeneration TKIs such as nilotinib or dasatinib. The first study report was by Rea et al. [38] . In that Stop 2G-TKI study, patients with CP-CML/AP-CML at diagnosis, receiving first-or subsequent-line dasatinib or nilotinib at any dose were enrolled. Of the 60 patients enrolled, 26 (43.3%) experienced a molecular relapse defined as the loss of a major molecular response (MMR). In univariate analysis, prior suboptimal response or TKI resistance was the only baseline factor associated with significantly worse outcome. The TFR for patients who were on 2G-TKI for suboptimal response/resistance vs. others was 62 vs. 23%, respectively. Relapses in patients with former suboptimal response or TKI resistance failed to show any specific aggressive features compared to those occurring in patients who received 2G-TKI first line or after intolerance to prior therapy. In contrast, the ENESTop trial demonstrated that there was no difference in the rates of TFR in patients who switched from imatinib to nilotinib for resistance, intolerance, or patients' choice [39] . Multiple other studies included patients who received dasatinib or nilotinib such as DADI [31] , DASfree [27] , ENESTfreedom [26] , ENESTgoal [40] , and ENESTpath [41] . (Details in Table 2 ) The ENESTfreedom [26] trial evaluated stopping nilotinib in patients with chronic-phase CML who were receiving frontline nilotinib therapy for at least 2 years and were in sustained deep molecular response. Of the 190 patients enrolled, 52% of patients maintained TFR. Both the DASfree [27] study and DADI [31] trial enrolled patients who were on dasatinib either as first or subsequent line. The TFR was 63% Longer duration on dasatinib prior to DC is associated with higher rates of retained MMR (63% at 1 year)
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Imatinib dasatinib N/A at 1 year and 49% at 6 months in the DASfree and DADI trial, respectively. Several other studies are currently ongoing, evaluating switching to 2G-TKI after imatinib then stopping. In the D-STOP trial [36] , patients who had undetectable disease with imatinib therapy were switched to dasatinib. Patients who maintained undetectable disease for 2 years discontinued dasatinib therapy. Of the 65 patients enrolled, 54 maintained undetectable disease and discontinued therapy. With a median follow up of 16.2 months, the estimated TFS (treatment-free survival) at 1 year was 63%. As expected, most relapses occurred in the first 6 months.
To date, the rates of TFR after second-generation TKI do not appear to be superior to imatinib. However, more patients who receive 2G-TKI will achieve a deep molecular response earlier and may be eligible to stop. In addition, a shorter treatment duration maybe sufficient with 2G-TKI as suggested by the ENESTfreedom [26] and DADI trial [31] .
Can a Second Discontinuation Be Attempted?
Two studies have reported on the prospect of second discontinuation, both with very different results. In the study by Pagliardini, 67 patients who had previously discontinued TKI and achieved another sustained deep molecular response discontinued therapy. Of those, 43 and 55% resumed TKI after first discontinuation for loss of undetectable molecular disease and loss of MMR, respectively. Patients re-initiated TKI with loss of MMR in the second discontinuation. With a median follow-up of 21.5 months, 44% of patient remained in MMR and did not restart drug [42] . In contrast, in another study by Matsuki et al., patients with CP-CML who had previously attempted discontinuation, and restarted for a PCR level > 100 attempted a second discontinuation. Of the 10 patients who were enrolled, all but one patient lost MMR and restarted the drug [43] . The most likely explanation for the markedly different results is the trigger for the first restart. In the study by Pagliardini, 43% restarted the first time when the PCR was detectable. The second restart was triggered by loss of MMR. So, it is possible that many of those patients would not have needed to restart the first time (17) . In the long-term follow-up of the STIM trial, 15 patients attempted a second discontinuation. Of those, 5 needed to restart therapy [24••, 44] What Is the Appropriate Trigger to Restart TKI?
The trigger to restart TKIs has differed in various studies. After realizing that some patients may have persistent detectable disease, but have no evidence of disease progression, the threshold for restarting TKI was raised. The A-STIM trial was the first study to restart TKI at loss of MMR [34] . The A-STIM (According to Stop Imatinib) was a multicenter observational Study, which evaluated the safety of major molecular response (MMR) loss as a trigger for restarting tyrosine kinase. Of the 80 patients with CP-CML enrolled, 29 patients (36%) lost MMR after a median of 4 months off therapy. Fluctuation of BCR-ABL transcript levels below the MMR threshold was observed in 31% of patients after discontinuing imatinib. Treatment-free remission was 64% at 12 and 24 months and 61% at 36 months. Based on that data, several studies used loss of MMR as the trigger to restart TKI [34] . Although definition of MR (molecular relapse) leading to treatment resumption was slightly different in various stopping TKI studies, a common feature is most cases of molecular recurrence occur during the first few months (mainly up to 6 months) after imatinib cessation. Based on that, monthly PCR testing is recommended in the first 6 months of therapy.
TKI Withdrawal Syndrome
TKI withdrawal syndrome, a musculoskeletal pain syndrome, was first described by Richter et al., from the EURO-SKI study. The musculoskeletal pain (muscle tenderness, sometimes resembling polymyalgia rheumatica) began or worsened within 1-6 weeks after stopping imatinib therapy in about 30%(15 out of the first 50) of patients. Median duration of imatinib therapy was 9 years, the severity was graded 1-2 [45•] . Therapy is mainly supportive with NSAIDs and/or steroids. Symptoms also rapidly resolved in patients who restarted imatinib. Similarly, in the KID study, musculoskeletal pain after IM discontinuation occurred in approximately 30% of patients, though no patient was restarted on imatinib due to musculoskeletal pain. Interestingly, patients who developed imatinib withdrawal syndrome were more likely to remain in remission [35] .
Conclusion and Future Directions
Available data suggest that most patients will need to continue TKI indefinitely. For 100 newly diagnosed patients, about 50% will achieve a deep molecular response. Of those, approximately 25 (50%) will need to restart therapy. Based on that, 75% of patients with CML will require lifelong tyrosine kinase inhibitor therapy. Some may argue that, given patients have a normal life expectancy on TKI therapy, no more research is needed in CML. However, that is not true for all patients and treating physicians. Better therapies are needed to eradicate CML and truly cure more patients with CML, that is, patients are off drug with no evidence of disease. Several compounds are effective in the therapy of CML. CML is an immune-sensitive disease; therefore, immunotherapies (e.g., PD-1 inhibitors and NK cell activators) may have a future role in CML therapy. Other possibilities include proteasome inhibition, bcl-2 inhibition, TKI combinations, and ABL-001. In order to move CML research forward, several investigators in the USA are collaborating to form a CML consortium with the ultimate goal of curing this disease.
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